Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 24(22): 11768-11772, 2020 11.
Article in English | MEDLINE | ID: mdl-33275246

ABSTRACT

Occurrence of chest pain during an allergic reaction is a typical manifestation of the Kounis syndrome, defined in 1991 by Nicholas Kounis and George Zavras as an "allergic angina", whose clinical course can range from a simple coronary spasm without troponin elevation to an acute myocardial infarction with all the possible complications, including sudden cardiac death. The full pathogenetic mechanisms are still not fully understood, and this is one of the reasons why it is underestimated in the emergency practice; on the other hand, an immediate identification and an appropriate treatment could prevent the occurrence of the most serious consequences. In this article we report the case study of a patient with Kounis syndrome and we review the literature on this uncommon disease; it is fundamental to consider Kounis syndrome as a possible cause of chest pain in patients admitted in the emergency department with an ongoing allergic reaction.


Subject(s)
Acute Coronary Syndrome/diagnosis , Chest Pain/diagnosis , Electrocardiography , Kounis Syndrome/diagnosis , Acute Coronary Syndrome/drug therapy , Acute Coronary Syndrome/physiopathology , Aged , Chest Pain/drug therapy , Chest Pain/physiopathology , Emergency Service, Hospital , Female , Humans , Hypersensitivity , Kounis Syndrome/drug therapy , Kounis Syndrome/physiopathology
2.
Eur Rev Med Pharmacol Sci ; 23(17): 7517-7518, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31539140

ABSTRACT

Capnocytophaga canimorsus is a Gram-negative rods frequently isolated as commensal in the saliva of pets that can be transmitted to humans. We report a case of septic shock caused by this pathogen. A 78-year-old man affected by diabetes and hypertension was admitted for fever in our Emergency Department. He reported fever (37.7°C) with normal values of blood pressure, heart rate and saturation of oxygen. Laboratory studies showed increased values of procalcitonin and normal white-cell level. Blood cultures were collected and an empirical antibiotic therapy was started. He reported six days earlier a bite of a dog at the right hand. During the following days the patient presented a deterioration of clinical conditions with fever, asthenia and comparison of petechial lesions. C. canimorsus was isolated from blood cultures. He was treated with fluids and appropriate antibiotic therapy with a full recovery. Dog wounds are frequent minor injuries with an underestimated worldwide incidence because only few patients develop complications. C. canimorsus could be an emerging cause of sepsis, also in immunocompetent patients. The current understanding of risk factors for C. canimorsus associated sepsis and a prompt approach to anamnesis and treatment of early stage injuries, could have a considerable medical outcome.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Capnocytophaga/isolation & purification , Dog Diseases/microbiology , Gram-Negative Bacterial Infections/diagnosis , Shock, Septic/microbiology , Aged , Animals , Comorbidity , Dogs , Gram-Negative Bacterial Infections/blood , Gram-Negative Bacterial Infections/drug therapy , Humans , Male , Shock, Septic/drug therapy , Treatment Outcome
3.
Dement Geriatr Cogn Disord ; 10(2): 139-47, 1999.
Article in English | MEDLINE | ID: mdl-10026388

ABSTRACT

The effectiveness of long-term treatment of Alzheimer's disease with cholinesterase inhibitors is a matter of controversy. We evaluated the effects of prolonged treatment with eptastigmine in 176 patients with mild to moderate Alzheimer's disease participating in the open-label extension phase of a 25-week double-blind, placebo-controlled trial of eptastigmine. The effects of eptastigmine on cognition and daily functioning were evaluated with the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-Cog) and the Instrumental Activities of Daily Living (IADL) scale, respectively. Safety was monitored by physical examination, laboratory tests, vital functions and electrocardiogram measurements and by the assessment of adverse events. One hundred and fifty-three patients (87%) completed 1 year of treatment, 77 patients (44%) 18 months and 33 patients (19%) 2 years of treatment. Patients treated for 2 years showed an improvement of mean ADAS-Cog scores compared to baseline for 31 weeks and mean IADL scores remained close to baseline for 25 weeks. Cognitive and functional scores then worsened as expected in this progressive disease. After 2 years, patients deteriorated compared to baseline by 13.4 points on the ADAS-Cog and 6.1 points on IADL. Historical untreated controls with identical disease severity are expected to have an annual worsening of approximately 10.9 points on ADAS-Cog and 4.9 points on IADL. Thus patients treated with eptastigmine for 2 years had a benefit of 8.5 points on ADAS-Cog and 3.8 points on IADL. These benefits translate to about 9 months difference between eptastigmine-treated patients and untreated historical patients. The drug was generally well tolerated with 14 patients (7.9%) withdrawing due to adverse events. Adverse events, not necessarily drug-related, were recorded in 66 patients (37.5%) and were transient and generally mild in severity. This study indicates that prolonged treatment with eptastigmine is safe and produced a clinically long-term benefit in patients with Alzheimer's disease.


Subject(s)
Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/therapeutic use , Physostigmine/analogs & derivatives , Activities of Daily Living , Adult , Aged , Aged, 80 and over , Cholinesterase Inhibitors/adverse effects , Cognition , Disease Progression , Double-Blind Method , Drug Monitoring , Electrocardiography , Female , Humans , Male , Middle Aged , Physostigmine/adverse effects , Physostigmine/therapeutic use
4.
Carbohydr Res ; 255: 125-32, 1994 Mar 04.
Article in English | MEDLINE | ID: mdl-8181002

ABSTRACT

The aim of this study was to set up a depolymerization process which resulted in the formation of a low molecular weight dermatan sulphate (LMWDS), retaining the chemical properties possessed by native dermatan sulphate (DS), fundamental for the expression of its specific biological activity. The depolymerization of DS by a beta elimination process led to the production of oligosaccharide chains having a 4,5 unsaturated uronic acid at the nonreducing end. The chemical evaluation has shown that the most important parameters (degree of sulphation, sulphate to carboxyl ratio, and specific rotation) have not undergone any particular modification compared to native DS. The biochemical results demonstrate that the LMWDS obtained retains most, if not all, of the specific biological activity. The reduction in molecular weight significantly enhanced the bioavailability of the product after subcutaneous administration.


Subject(s)
Anticoagulants/pharmacokinetics , Dermatan Sulfate/analogs & derivatives , Dermatan Sulfate/pharmacokinetics , Animals , Anticoagulants/chemistry , Biological Availability , Carbohydrate Sequence , Molecular Sequence Data , Molecular Weight , Rabbits , Rats , Thrombosis/therapy
5.
J Exp Med ; 173(4): 1007-15, 1991 Apr 01.
Article in English | MEDLINE | ID: mdl-1706750

ABSTRACT

Transgenic murine lines have been constructed that express a chimeric class I molecule composed of the alpha 1 and alpha 2 domains of HLA-A2.1 and the alpha 3, transmembrane, and cytoplasmic domains of H-2Kb. Upon immunization with influenza virus, transgenic mice developed a strong A2.1Kb-restricted cytotoxic T lymphocyte (CTL) response specific for the same matrix protein epitope that serves as the dominant A2.1-restricted determinant in the equivalent human response. Fine specificity analysis of CTL clones using truncated peptides revealed strong similarity between the response repertoire of transgenic mice and that previously reported using influenza-specific A2.1-restricted CTL clones from humans. This suggests that even when considering T cell responses by different species, the alpha 1 and alpha 2 domains of the restriction element play a dominant role in determining the CTL specific repertoire. Thus, substituting the alpha 3 domain of A2.1 with a murine counterpart has permitted development of a transgenic strain that should serve as an excellent model system in studies of HLA-restricted responses.


Subject(s)
Antigens, Viral/immunology , H-2 Antigens/immunology , HLA-A Antigens/immunology , Influenza A virus/immunology , Major Histocompatibility Complex , T-Lymphocytes, Cytotoxic/immunology , Animals , Cytotoxicity, Immunologic , Epitopes , H-2 Antigens/genetics , HLA-A Antigens/genetics , Mice , Mice, Transgenic , Recombinant Fusion Proteins , Spleen/immunology , Viral Matrix Proteins/immunology
6.
Ric Clin Lab ; 16(2): 413-6, 1986.
Article in English | MEDLINE | ID: mdl-3787102

ABSTRACT

On the basis of a functional model of the system removing immune complexes from blood (SRIC), we may consider essential mixed cryoglobulinemia (EMC) as a condition of SRIC insufficiency due to an excessive input of immune complexes. Thus, we tried to lower the global input to SRIC in 10 symptomatic EMC patients by giving them a hypoantigenic diet for 2-3 weeks, with a gradual return on free diet in the subsequent 12 weeks. After 10-60 days from the beginning of diet, all patients experienced significant reductions of symptoms' intensity (p = 0.005), of cryoprecipitate protein content (p = 0.025) and of circulating immune complex-like material (p = 0.035). A reduction of the prednisone dosage (p less than 0.005) in the 7 patients on continuous treatment was made possible. After the return on free diet, 6 patients had a relapse. Although preliminary, our results show that a hypoantigenic diet is able to lower circulating cryoglobulin levels and to clinically improve the EMC, probably by making the SRIC more functionally efficient.


Subject(s)
Cryoglobulinemia/diet therapy , Adult , Aged , Antigen-Antibody Complex/metabolism , Complement System Proteins/analysis , Cryoglobulins/metabolism , Female , Humans , Male , Middle Aged , Plasmapheresis , Polyethylene Glycols/pharmacology , Prednisone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...